HK1247789A1 - 用於治疗水肿的组合物和方法 - Google Patents

用於治疗水肿的组合物和方法 Download PDF

Info

Publication number
HK1247789A1
HK1247789A1 HK18107279.7A HK18107279A HK1247789A1 HK 1247789 A1 HK1247789 A1 HK 1247789A1 HK 18107279 A HK18107279 A HK 18107279A HK 1247789 A1 HK1247789 A1 HK 1247789A1
Authority
HK
Hong Kong
Prior art keywords
methods
edema
compositions
treatment
agent
Prior art date
Application number
HK18107279.7A
Other languages
English (en)
Chinese (zh)
Inventor
Mehrara Babak
Gardenier Jason
SAVETSKY Ira
ARAS Omer
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of HK1247789A1 publication Critical patent/HK1247789A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK18107279.7A 2015-02-05 2016-02-05 用於治疗水肿的组合物和方法 HK1247789A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112273P 2015-02-05 2015-02-05
US62/112,273 2015-02-05
PCT/US2016/016680 WO2016127013A1 (en) 2015-02-05 2016-02-05 Compositions and methods for treatment of edema

Publications (1)

Publication Number Publication Date
HK1247789A1 true HK1247789A1 (zh) 2018-10-05

Family

ID=56564721

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107279.7A HK1247789A1 (zh) 2015-02-05 2016-02-05 用於治疗水肿的组合物和方法

Country Status (8)

Country Link
US (5) US10251871B2 (https=)
EP (1) EP3253211B1 (https=)
JP (2) JP6704403B2 (https=)
CN (2) CN114588154A (https=)
AU (2) AU2016215173B2 (https=)
ES (1) ES3040783T3 (https=)
HK (1) HK1247789A1 (https=)
WO (1) WO2016127013A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127013A1 (en) * 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
CA3033863C (en) * 2016-08-18 2021-09-14 Memorial Sloan Kettering Cancer Center Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema
EP4603148A3 (en) * 2018-09-14 2025-10-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
AU2019375206A1 (en) * 2018-11-05 2021-06-24 Apramitha Innovations Private Limited Teriflunomide topical pharmaceutical compositions
CA3175866A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
CN112642065B (zh) * 2020-12-28 2022-08-02 锐可医疗科技(上海)有限公司 激光治疗仪及存储介质
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JPWO2005011669A1 (ja) * 2003-08-05 2006-09-14 大日本住友製薬株式会社 経皮投与用医薬組成物
CA2644311C (en) * 2006-03-01 2012-07-10 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
ES2563288T3 (es) * 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP5213852B2 (ja) * 2006-06-15 2013-06-19 シャンハイ ゲノミックス インク 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用
MX337408B (es) * 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
CA2741954A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
WO2016127013A1 (en) * 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
US10292961B2 (en) * 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule

Also Published As

Publication number Publication date
US20230241043A1 (en) 2023-08-03
JP6704403B2 (ja) 2020-06-03
CA2975879A1 (en) 2016-08-11
US20180028514A1 (en) 2018-02-01
US10251871B2 (en) 2019-04-09
AU2016215173A1 (en) 2017-08-24
EP3253211A1 (en) 2017-12-13
US12144805B2 (en) 2024-11-19
ES3040783T3 (en) 2025-11-04
US11583523B2 (en) 2023-02-21
AU2016215173B2 (en) 2019-11-21
CN114588154A (zh) 2022-06-07
US20200016137A1 (en) 2020-01-16
AU2020201161A1 (en) 2020-03-05
US20210069164A1 (en) 2021-03-11
AU2020201161B2 (en) 2021-07-15
JP2018504436A (ja) 2018-02-15
US20250235436A1 (en) 2025-07-24
CN107427007A (zh) 2017-12-01
JP6926263B2 (ja) 2021-08-25
JP2020114830A (ja) 2020-07-30
WO2016127013A1 (en) 2016-08-11
CN107427007B (zh) 2022-02-11
EP3253211B1 (en) 2025-06-11
EP3253211A4 (en) 2018-10-31
US10874651B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
HK1247789A1 (zh) 用於治疗水肿的组合物和方法
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
PH12017502107A1 (en) Triazole agonists of the apj receptor
CA2956871C (en) Compounds active towards bromodomains
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2018006223A (es) Moduladores de ror-gamma.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MY199705A (en) Heterocyclic compounds as immunomodulators
MX2018006207A (es) Compuestos heterociclicos como inmunomoduladores.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2018019823A8 (en) Administration and dosage of diaminophenothiazines
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
EP4356962A3 (en) Selective il-6-trans-signalling inhibitor compositions
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
WO2016130581A3 (en) Combination cancer therapy
MX2017010422A (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
WO2017079403A3 (en) Polymeric nanoparticles
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX381311B (es) Método para el tratamiento de prurito y/o comezón.